

Registration Opens for SMi's 21st Annual Pain Therapeutics Virtual Conference

SMi Report, 21st Annual Pain Therapeutics Virtual Conference will explore cutting edge drug discovery science, key clinical-stage pain therapies in the pipeline

LONDON, CENTRAL LONDON, UNITED KINGDOM, January 14, 2021 /EINPresswire.com/ -- SMi Group are pleased to announce the [21st Annual Pain Therapeutics Conference](#), taking place as a virtual conference with online access only on 11th – 11th May 2021.

The [conference will focus on looking](#) into research within pain therapeutics. In particular, the long-term (HEAL) initiative will be discussed and its role in advancing research to reduce the risks of opioid use and misuse and improve pain management, thereby reducing reliance on opioids and the national opioid public health crisis. Talks will also address the importance of sex, gender and race in pain research, including biomarkers, molecular targets, clinical and experimental models of pain.

The [conference also address](#) cutting edge drug discovery science, preclinical development trends, analysis of key clinical-stage pain therapies, with a focus on highlighting the importance of biomarker discovery and its contribution to early stage studies on pain. This will be topped off with a panel debate on rethinking pain clinical trials during the COVID-19 pandemic. And further look into treating painful osteoarthritis of the knee with a novel anti NGF, anti-TNFa bispecific fusion protein as well as therapeutic novelties signifying a paradigm shift in migraine prevention.

You can download the brochure at www.pain-therapeutics.co.uk.

`□

Interested parties should register at <http://www.pain-therapeutics.co.uk/pr1>

Event Highlights:



SMi Group Proudly Presents the 21st Annual conference on

Pain Therapeutics

Explore cutting edge drug discovery science and key clinical-stage pain therapies in the pipeline

CONFERENCE: 10TH-11TH MAY 2021

VIRTUAL CONFERENCE: ONLINE ACCESS ONLY

CHAIRS FOR 2021:

- Michael Scherz, Founder and CEO, Melix Pharma
- Naheed Mirza, Early Development Pain & CNS Specialist

FEATURED 2021 SPEAKERS INCLUDE:

- Iain Chessell, Global Head of Neuroscience, BioPharmaceuticals Research & Development, AstraZeneca
- Mihail Kalichev, Director, in vivo Neurology, Ipsen
- Dalma Sugar, Director Medical Affairs, Teva Pharmaceuticals
- Achim Kries, Pain Genetics Lead, Eli Lilly
- Jun Chen, Senior Scientist, Genentech
- Richard Mellamou, Chief Medical Officer and EVP, Celligium Pharmaceuticals
- Guido Kogejovic, Chief Scientific Officer, Allogix Pharmaceuticals
- Randall Kaye, Chief Medical Officer, Neurana Pharmaceuticals
- ...and many more!

KEY REASONS TO ATTEND THE VIRTUAL CONFERENCE:

- Discover which innovative new therapies are driving critical development including case studies from Navamand and Vopagenic
- Examine the best strategies to generate more funding in pain research clinical trials to alleviate the issue of underfunding
- Explore how COVID-19 has changed the experience of clinical trials and presented an opportunity to reform the way we approach data verification, data analysis and data collection
- Understand the role of biomarkers in evaluating target engagement of new drugs and predicting analgesic efficacy
- Virtual Conference Benefits include virtual exhibition booths packed with information, networking features to chat and share contact details with other attendees, and virtual meetings and networking socials. For full details see p.3

SPONSORED BY

Transpharmation
Science that translates into results

CPD Accredited | SMi Pharma | www.pain-therapeutics.co.uk
EASMP Pharma | Register online or fax your registration to +44 (0) 870 9090 712
F&M Pharma | or call +44 (0) 870 9090 711

Pain Therapeutics - Download Brochure

- Discover which innovative new therapies are driving clinical development including case studies from Novaramed and Vapogenix
- Examine the best strategies to generate more funding in pain research clinical trials to eliminate the issue of underfunding
- Explore how COVID-19 has changed the experience of clinical trials and presented an opportunity to reform the way we approach data verification, data analysis and data collection
- Understand the role of biomarkers in evaluating target engagement of new drugs and predicting analgesic efficacy
- Virtual Conference Benefits include virtual exhibition booths packed with information, networking features to chat and share contact details with other attendees, and virtual meetings and networking socials.

The conference is chaired by Michael Scherz, Founder and CEO, Metys Pharma and Naheed Mirza, Early Development Pain & CNS Specialist

Confirmed Speakers:

- Bain Chessell, Global Head of Neuroscience, Biopharmaceuticals Research & Development, AstraZeneca
- Mikhail Kalinichev, Director, in vivo Neurology, Ipsen
- Dalma Sugar, Director Medical Affairs, Teva Pharmaceuticals
- Achim Kless, Pain Genetics Lead, Eli Lilly
- Jun Chen, Senior Scientist, Genentech
- Richard Malamut, Chief Medical Officer and EVP, Collegium Pharmaceuticals
- Guido Koopmans, Chief Scientific Officer, Algiax Pharmaceuticals
- Randall Kaye, Chief Medical Officer, Neurana Pharmaceuticals

The full agenda and speaker line-up can be viewed online at <http://www.pain-therapeutics.co.uk/pr1>

Proudly sponsored by: Transpharmation

For sponsorship enquiries contact Alia Malick on +44 (0)20 7827 6164 or amalick@smi-online.co.uk

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6162 or ssapal@smi-online.co.uk

SMI's 21st Annual Pain Therapeutics Virtual Conference

Conference: 10th – 11th May 2021

Virtual Conference: Online Access Only

<http://www.pain-therapeutics.co.uk/pr1>

#SMiPain

--- ENDS ---

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Simi Sapal

SMi Group

+442078276000

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/534518341>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.